NASDAQ · SBFM
Healthcare · Drug Manufacturers - Specialty & Generic
$0.90
Up+$0.06 (+6.98%)
Updated Sep 20, 2026, 3:14 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
SBFM closed at $0.90 after 19 trading sessions, down 22.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $0.82 | $0.8999 | $0.82 | $0.8998 | 157.77K |
| Sep 17, 2026 | $1.01 | $1.01 | $0.8411 | $0.8411 | 355.42K |
| Sep 16, 2026 | $1.022 | $1.0575 | $1.015 | $1.03 | 126.52K |
| Sep 15, 2026 | $1.0678 | $1.0678 | $1.025 | $1.03 | 92.73K |
| Sep 14, 2026 | $1.05 | $1.08 | $1.05 | $1.07 | 63.27K |
| Sep 11, 2026 | $1.10 | $1.1149 | $1.05 | $1.06 | 99.92K |
| Sep 10, 2026 | $1.14 | $1.14 | $1.08 | $1.08 | 144.02K |
| Sep 9, 2026 | $1.14 | $1.15 | $1.11 | $1.12 | 87.08K |
| Sep 8, 2026 | $1.18 | $1.235 | $1.135 | $1.15 | 288.18K |
| Sep 4, 2026 | $1.14 | $1.14 | $1.11 | $1.14 | 82.96K |
| Sep 3, 2026 | $1.168 | $1.17 | $1.11 | $1.11 | 126.64K |
| Sep 2, 2026 | $1.14 | $1.19 | $1.12 | $1.17 | 129.98K |
| Sep 1, 2026 | $1.12 | $1.15 | $1.11 | $1.13 | 107.19K |
| Aug 31, 2026 | $1.14 | $1.23 | $1.1046 | $1.12 | 368.3K |
| Aug 28, 2026 | $1.28 | $1.28 | $1.14 | $1.15 | 451.76K |
| Aug 27, 2026 | $1.25 | $1.30 | $1.18 | $1.27 | 1.02M |
| Aug 26, 2026 | $1.30 | $1.31 | $1.01 | $1.24 | 9.36M |
| Aug 25, 2026 | $1.15 | $1.1662 | $1.1211 | $1.14 | 52.51K |
| Aug 24, 2026 | $1.17 | $1.17 | $1.12 | $1.16 | 84.35K |
The latest Smart Investors Daily articles mentioning SBFM.
SBFM research
Company profile and research snapshot.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2025 | Aegis Capital | Buy | — |
| Dec 5, 2024 | Aegis Capital | Buy | — |
| Aug 7, 2023 | Aegis Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 4, 2026
Dienogest is first-line therapy for pelvic pain associate with endometriosis The endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ...
Yahoo · Aug 4, 2026
Pharmaceutical firm Sunshine Biopharma Inc. (NASDAQ:SBFM) on Tuesday said it received regulatory approval to introduce its 2mg generic Dienogest tablets to the Canadian market. The significant milestone marks the company’s strategic expansion into women’s healthcare, specifically targeting first-line therapy for pelvic pain associated with endometriosis. Read Also: Sunshine Biopharma Stock Rallies On Canadian Approval For Generic Amoxicillin The generic prescription drugs maker in June implement
Yahoo · Jul 28, 2026
FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of ...
accessnewswire.com · Oct 28, 2025
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ: SBFM ) is quickly establishing which side of that line it's on.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SBFM.
